文献速递肺栓塞与肺血管病

Selexipag治疗慢性血栓栓塞性肺动脉高压

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
PubMed 文献 · Eur Respir J · 2022-07-07

这项多中心随机双盲安慰剂对照研究纳入78例日本不可手术CTEPH或术后/球囊肺血管成形术后持续/复发肺动脉高压患者,评估Selexipag疗效。主要终点20周肺血管阻力变化在Selexipag组为-98.2±111.3 dyn·s·cm-5,安慰剂组为-4.6±163.6 dyn·s·cm-5,组间平均差-93.5 dyn·s·cm-5(95%CI -156.8至-30.3,p=0.006)。心脏指数和Borg呼吸困难评分也显著改善,但6分钟步行距离和WHO功能分级未显著改善。

要点

  • Selexipag显著降低CTEPH患者肺血管阻力,平均差-93.5 dyn·s·cm-5(p=0.006)。
  • 心脏指数和Borg呼吸困难评分较安慰剂显著改善。
  • 6分钟步行距离和WHO功能分级未显著改善,运动能力未变。

核心结论

  • Selexipag显著改善CTEPH患者肺血管阻力及其他血流动力学指标,但运动能力未改变,需进一步大规模研究证实其作用。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照研究,纳入78例日本不可手术CTEPH或肺动脉内膜剥脱术和/或球囊肺血管成形术后持续/复发肺动脉高压患者,随机接受安慰剂或Selexipag。

主要发现

  • 肺血管阻力变化:Selexipag组-98.2±111.3 dyn·s·cm-5,安慰剂组-4.6±163.6 dyn·s·cm-5,平均差-93.5 dyn·s·cm-5(95%CI -156.8至-30.3,p=0.006)。
  • 心脏指数变化较安慰剂显著改善(p<0.001)。
  • Borg呼吸困难评分变化较安慰剂显著改善(p=0.036)。
  • 6分钟步行距离和WHO功能分级未显著改善。
  • Selexipag组常见不良事件与前列环素类似物一般观察到的相符。

临床怎么用

  • 对于不可手术CTEPH或术后持续/复发肺动脉高压患者,Selexipag可考虑用于改善肺血管阻力等血流动力学指标。
  • 需注意Selexipag未显著改善运动能力,临床决策应综合评估。

局限性

  • 样本量较小(78例日本患者),需进一步大规模研究证实Selexipag在CTEPH中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) remain limited. Selexipag, an oral selective IP prostacyclin receptor agonist approved for pulmonary arterial hypertension, is a potential treatment option for CTEPH. METHODS: In this multicentre, randomised, double-blind, placebo-controlled study, 78 Japanese patients with inoperable CTEPH or persistent/recurrent pulmonary hypertension after pulmonary endarterectomy and/or balloon pulmonary angioplasty were randomly assigned to receive placebo or selexipag. The primary end-point was the change in pulmonary vascular resistance (PVR) from baseline to week 20. Secondary end-points were changes in other haemodynamic parameters: 6-min walk distance (6MWD), Borg dyspnoea scale score, World Health Organization (WHO) functional class, EuroQol five-dimension five-level tool and N-terminal pro-brain natriuretic peptide. RESULTS: The change in PVR was -98.2±111.3 dyn·s·cm-5 and -4.6±163.6 dyn·s·cm-5 in the selexipag and placebo groups, respectively (mean difference -93.5 dyn·s·cm-5; 95% CI -156.8 to -30.3; p=0.006). The changes in cardiac index (p<0.001) and Borg dyspnoea scale score (p=0.036) were also significantly improved over placebo. 6MWD and WHO functional class were not significantly improved. The common adverse events in the selexipag group corresponded to those generally observed following administration of a prostacyclin analogue. CONCLUSION: Selexipag significantly improved PVR and other haemodynamic variables in patients with CTEPH, although exercise capacity remained unchanged. Further large-scale investigation is necessary to prove the role of selexipag in CTEPH.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Ogo T, Shimokawahara H, Kinoshita H, et al. Selexipag for the treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J. 2022. PMID: 34824052. doi:10.1183/13993003.01694-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。